Approval · Notice of Compliance 33676 · 2024
CLINIMIX E: Notice of Compliance 33676
Issued July 19, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33676
- Date
- July 19, 2024
- Company
- Baxter CorporationMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to package labels
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CLINIMIX E | Not yet assigned | — |
Medicinal ingredients
- L-ISOLEUCINE 240 MG per 100ML
- L-LEUCINE HCL 310 MG per 100ML
- L-PHENYLALANINE HCL 310 MG per 100ML
- L-PROLINE 210 MG per 100ML
- L-THREONINE 210 MG per 100ML
- L-TRYPTOPHAN 90 MG per 100ML
- L-VALINE 230 MG per 100ML
- L-LYSINE HCL 290 MG per 100ML
- MAGNESIUM CHLORIDE 24 MG per 100ML
- METHIONINE 290 MG per 100ML
- POTASSIUM PHOSPHATE DIBASIC 261 MG per 100ML
- SODIUM ACETATE 205 MG per 100ML
- SODIUM CHLORIDE 58.5 MG per 100ML
- L-TYROSINE 20 MG per 100ML
- L-ALANINE 1.04 G per 100ML
- DEXTROSE 10 G per 100ML
- GLYCINE 1.04 G per 100ML
- HISTIDINE 220 MG per 100ML
- L-ARGININE 520 MG per 100ML
- TRYPTOPHAN 90 MG per 100ML
- DEXTROSE 16.6 G per 100ML